Physician profile
David Landess
NPI 1831260645
$4,221.32
in general payments reported to CMS, 2019-2025
27 companies · $922 in 2025
The $922 reported for 2025 was more than what 90% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $696 · 2020: $184 · 2021: $413 · 2022: $412 · 2023: $490 · 2024: $1,104 · 2025: $922.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,499 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,498.50 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $624.31 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $557.97 | 2019-2023 | |
| Bausch & Lomb Americas INC. | $512.31 | 2022-2025 | Biotrue, Infuse, Vyzulta |
| Harrow Eye, LLC | $339.36 | 2023-2025 | Vevye, Iheezo |
| Alcon Vision LLC | $325.60 | 2019-2025 | Eysuvis, Tryptyr, Rocklatan |
| Abbvie INC. | $243.06 | 2022-2025 | |
| Oyster Point Pharma, INC. | $180.58 | 2023-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Tarsus Pharmaceuticals, INC. | $151.43 | 2024-2025 | Xdemvy |
| Glaukos Corporation | $149.89 | 2022-2025 | Kxl System (Not Refurbished), Ce-Marked Kxla System, Istent Trabecular Micro-Bypass System Model Is3 |
| Lkc Technologies, INC. | $142.33 | 2024-2025 | |
| Coopervision INC. | $137.26 | 2019-2025 | Clariti Contact Lens, Myday Contact Lens, Paragon Crt |
| Allergan, INC. | $127.54 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $110.99 | 2022-2025 | Acthar |
| Amgen INC. | $92.50 | 2024-2025 | Tepezza |
| Johnson & Johnson Vision Care, INC. | $89.54 | 2019-2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Thea Pharma INC. | $78.22 | 2023-2025 | Iyuzeh |
| Shire North American Group INC | $64.58 | 2019 | |
| Astellas Pharma US INC | $47.44 | 2024 | Izervay |
| Apellis Pharmaceuticals, INC. | $46.42 | 2023-2025 | |
| Sun Pharmaceutical Industries INC. | $38.10 | 2023-2025 | Cequa |
| Genentech USA, INC. | $34.71 | 2022-2023 | Vabysmo |
| Aerie Pharmaceuticals, INC. | $25.00 | 2020-2021 | |
| Dompe US, INC. | $24.91 | 2024 | Oxervate |
| Regeneron Healthcare Solutions, INC. | $21.91 | 2024 | Eylea Hd |
| Horizon Therapeutics Plc | $20.90 | 2021 | |
| Quidel Corporation | $19.94 | 2019 | |
| Kala Pharmaceuticals, INC. | $14.52 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Landess listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.